Is ruxolitinib ointment available in China?

Ruxolitinib ointment (Opzelura) is a new topical drug mainly used to treat skin diseases such as atopic dermatitis and non-segmental alopecia areata. Its active ingredient ruxolitinib is a selective Januskinase (JAK) 1/2Inhibitors reduce the inflammatory response by inhibiting the JAK-STAT signaling pathway, thereby effectively alleviating the symptoms of itching and redness in patients with atopic dermatitis. In addition, ruxolitinib ointment is also the first JAK inhibitor approved by the FDA for the treatment of alopecia areata. It can promote the recovery of hair follicle function and hair regeneration by regulating abnormal activities of the immune system.

Ruxolitinib ointment is simple and convenient to use. Patients only need to apply the ointment thinly to the affected skin area and use it twice daily. However, as a powerful drug, patients should use it under the guidance of a doctor, especially during long-term treatment, to avoid potential side effects.

Currently, ruxolitinib ointment has not yet been launched in China, so patients cannot purchase this drug in domestic pharmacies. For patients in need, the only way to purchase them is through overseas channels. The price of foreign original drugs is relatively high, usually as high as more than 10,000 yuan. In contrast, the price of generic drugs from Bangladesh is more affordable, about a few hundred yuan, and the ingredients are basically the same as the original drugs. Therefore, many patients choose to purchase Bangladeshi generic drugs to reduce the cost of treatment.

Overall, ruxolitinib ointment provides a new treatment option for patients with atopic dermatitis and alopecia areata, especially those who have not responded well to traditional treatments. As the drug's application expands globally, it is expected that it will also enter the domestic market in the future, bringing benefits to more patients.